Chapel Hill, North Carolina
Cancer clinical trials in Chapel Hill, NC
130 cancer studies are recruiting participants at sites in Chapel Hill as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Chapel Hill at a glance
- 130 studies are recruiting at a site in Chapel Hill.
- By phase: Early Phase 1 (1), Phase 1 (10), Phase 1/2 (12), Phase 2 (41), Phase 2/3 (2), Phase 3 (31), No phase (16), Observational (17). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (74), industry (46), government (10).
- By research area: Breast Cancer (44), Lymphoma (40), Lung Cancer (20), Melanoma (11), Pancreatic Cancer (10), Prostate Cancer (5).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Chapel Hill
Basic details from each study's public record (the 30 most recently updated of 130). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT07069595 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT06058377 · updated
The Vanguard Study: Testing a New Way to Screen for Cancer
- No phase
- Ages 45 to 75
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT06995898 · updated
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
- No phase
- Ages 18 and older
- Female participants
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Study site
- UNC Cancer Hospital
- Registry record
- NCT07389967 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- Lineberger Comprehensive Cancer Center
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT05879926 · updated
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- University of North Carolina Medical Center
- Registry record
- NCT07174336 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.
Lung cancer studies recruiting in Chapel Hill
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- UNC Lineberger Comprehensive Cancer Center ( Site 3250)
- Registry record
- NCT07513376 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of North Carolina at Chapel Hill
- Registry record
- NCT07659782 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- University of North Carolina at Chapel Hill
- Registry record
- NCT07002034 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- University of North Carolina Medical Center
- Registry record
- NCT06119581 · updated
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Study site
- University of North Carolina at Chapel Hill
- Registry record
- NCT06667908 · updated
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- UNC Health - University of North Carolina
- Registry record
- NCT07288177 · updated
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT07293247 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.
Prostate cancer studies recruiting in Chapel Hill
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT03866382 · updated
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT06632977 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.
Melanoma studies recruiting in Chapel Hill
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- UNC Hospitals, The University of North Carolina at Chapel Hill
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chapel Hill, NC on ClinicalTrials.gov.
Lymphoma studies recruiting in Chapel Hill
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT06724237 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of North Carolina Medical Center ( Site 0136)
- Registry record
- NCT06890884 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT05675410 · updated
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University of North Carolina
- Registry record
- NCT06091254 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT06337318 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT03150693 · updated
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT04803201 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT05976763 · updated
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Phase 3
- Ages 65 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT07321652 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chapel Hill, NC on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Chapel Hill
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US035
- Registry record
- NCT07522073 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of North Carolina
- Registry record
- NCT07644559 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chapel Hill, NC on ClinicalTrials.gov.
Ask about studies near Chapel Hill
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in North Carolina
All North Carolina locations
429 studies recruiting across 60 cities.
Durham
182 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections